The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials
Abstract
The incidences of osteoporosis and renal insufficiency increase with age. We studied the influence of renal function on the safety and efficacy of risedronate 5 mg daily in osteoporotic women. Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment. Introduction: The incidences of both osteoporosis and renal insufficiency increase with age; thus, the effect of renal impairment on the safety and efficacy of osteoporosis treatments is a clinical concern. Risedronate is a pyridinyl bisphosphonate well established as safe and effective in the treatment and prevention of osteoporosis. Currently, there is little available information about the effect of bisphosphonate treatment in patients with renal insufficiency. This retrospective analysis was conducted to study the influence of renal function on the safety and efficacy of risedronate in a population of osteoporotic women. Materials and Methods: Combined data from nine randomized, double-blind, placebo-controlled phase III risedronate trials were analyzed. The patients in these studies had no markedly abnormal laboratory parameters that were considered clinically significant and no evidence of significant disease. This analysis included patients who received placebo (n = 4500) or risedronate 5 mg (n = 4496) for up to 3 years (average duration of exposure, 2 years) and who had renal impairment (creatinine clearance [CrCl] < 80 ml/min). CrCl was estimated by the Cockcroft and Gault method, based on age, weight, and serum creatinine. Patients were categorized as having mild (CrCl ≥50 to <80 ml/min), moderate (CrCl ≥30 to <50 ml/min), or severe (CrCl < 30 ml/min) renal impairment. Results: Of the patients studied, renal impairment at baseline was mild in 48% (mean [range] serum creatinine, 0.9 [0.4–1.6] mg/dl), moderate in 45% (1.1 [0.6–1.9] mg/dl), and severe in 7% (1.3 [0.7–2.7] mg/dl). In both the placebo and risedronate treatment groups, the patients with the most severe renal impairment were older and had more severe osteoporosis. The incidences of overall adverse events and of renal function-related adverse events were similar in the placebo and risedronate 5 mg groups regardless of renal function. Furthermore, evaluation of changes from baseline in serum creatinine revealed no difference in renal function between the placebo and risedronate 5 mg groups in any of the renal impairment subgroups at any time-point. In all three subgroups, risedronate effectively preserved BMD and reduced the incidence of vertebral fractures. Conclusions: These findings show that risedronate is safe and effective in osteoporotic women with age-related mild, moderate, or severe renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationLongitudinal Studies on the Rate of Decline in Renal Function with Age
Lindeman, R. D., Tobin, J., & Shock, N. W. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb07117.x · Cited by 1,578
Bisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Perspectives: How many women have osteoporosis now?
Dr. Melton, J. L. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100202 · Cited by 595
Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
Jones, C., McQuillan, G., Kusek, J., Eberhardt, M., Herman, W., Coresh, J., Salive, M., Jones, C., & Agodoa, L. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(98)70074-5 · Cited by 572
Prevalence and incidence of vertebral deformities
Melton, L. J., Lane, A. W., Cooper, C., Eastell, R., O'Fallon, W. M., & Riggs, B. L. (1993) · Osteoporosis International · doi:10.1007/bf01623271 · Cited by 517
Wallach, S., Cohen, S., Reid, D. M., Hughes, R. A., Hosking, D. J., Laan, R. F., Doherty, S. M., Maricic, M., Rosen, C., Brown, J., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 513
Self-citationLin, J., Knight, E. L., Hogan, M. L., & Singh, A. K. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088721.98173.4b · Cited by 413
Bostom, A. G., Kronenberg, F., & Ritz, E. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000022011.35035.f3 · Cited by 410
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381
Ensrud, K. E., Palermo, L., Black, D. M., Cauley, J., Jergas, M., Orwoll, E. S., Nevitt, M. C., Fox, K. M., & Cummings, S. R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101122 · Cited by 358
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
Mellström, D. D., Sörensen, O. H., Goemaere, S., Roux, C., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0286-7 · Cited by 350
Self-citationBrown, J. P., Kendler, D. L., McClung, M. R., Emkey, R. D., Adachi, J. D., Bolognese, M. A., Li, Z., Balske, A., & Lindsay, R. (2002) · Calcified Tissue International · doi:10.1007/s00223-002-2011-8 · Cited by 330
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
Hamdy, N. A. T., Kanis, J. A., Beneton, M. N. C., Brown, C. B., Juttmann, J. R., Jordans, J. G. M., Josse, S., Meyrier, A., Lins, R. L., & Fairey, I. T. (1995) · BMJ · doi:10.1136/bmj.310.6976.358 · Cited by 322
Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003) · Bone · doi:10.1016/s8756-3282(02)00946-8 · Cited by 254
Osteoporosis in chronic kidney disease
Cunningham, J., Sprague, S. M., Cannata-Andia, J., Coco, M., Cohen-Solal, M., Fitzpatrick, L., Goltzmann, D., Lafage-Proust, M.-H., Leonard, M., Ott, S., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.12.004 · Cited by 213
Eriksen, E. F., Melsen, F., Sod, E., Barton, I., & Chines, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00869-4 · Cited by 211
Self-citationFogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198
Relationship between age, renal function and bone mineral density in the US population
Klawansky, S., Komaroff, E., Cavanaugh, P. F., Mitchell, D. Y., Gordon, M. J., Connelly, J. E., & Ross, S. D. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1435-y · Cited by 196
Estimating the prevalence of renal insufficiency in seniors requiring long-term care
Garg, A. X., Papaioannou, A., Ferko, N., Campbell, G., Clarke, J.-A., & Ray, J. G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00412.x · Cited by 185
Coburn, J. W., Maung, H. M., Elangovan, L., Germain, M. J., Lindberg, J. S., Sprague, S. M., Williams, M. E., & Bishop, C. W. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.01.012 · Cited by 174
Design of the Fracture Intervention Trial
Black, D. M., Reiss, T. R., Nevitt, M. C., Cauley, J., Karpf, D., Cummings, S. R., & the Fracture Intervention Trial Research Group (1993) · Osteoporosis International · doi:10.1007/bf01623005 · Cited by 174
TREATMENT OF OSTEOPOROSIS WITH BISPHOSPHONATES
Watts, N. B. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70014-1 · Cited by 93
Renal secretion of diphosphonates in rats
Tröhler, U., Bonjour, J., & Fleisch, H. A. (1975) · Kidney International · doi:10.1038/ki.1975.70 · Cited by 85
Hooper, M. J., Ebeling, P. R., Roberts, A. P., Graham, J. J., Nicholson, G. C., dʼEmden, M. C., Ernst, T. F., & Wenderoth, D. (2005) · Climacteric · doi:10.1080/13697130500118126 · Cited by 55
Factors affecting renal function in 119 985 adults over three years
Ishida, K. (2001) · QJM · doi:10.1093/qjmed/94.10.541 · Cited by 31
Medical Management of Kidney Transplantation
Norby, S. M. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.10.1395-a · Cited by 8
Cited by
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.04.001 · Cited by 1,956
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialLong-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
Metadata
- Authors
- Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-01
- Volume
- 20
- Issue
- 12
- Pages
- 2105-2115
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2055233141
- Cited by
- 318
- References
- 33
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.